Decode Your Wellbeing: Age Reversal Just Reached Human Trials. Here Is What Is Real.
Age reversal left the petri dish and entered human trials this year. What that sentence does and does not mean.
Credit: AI-generated illustration. · HeadLines Decoded LLC
Illustration generated with AI (Grok).
Editor’s note. This is a report on published research and company disclosures as of July 19, 2026, with a dated update below. Nothing here should replace guidance from a clinician who knows your history.
The ER-100 trial (NCT07290244) is listed as recruiting on ClinicalTrials.gov. The registry describes an early safety trial (phase 1) with 18 planned participants, 12 with open-angle glaucoma and 6 with the optic-nerve stroke NAION, and gives a start date of March 2, 2026 (record last updated May 19, 2026).
On October 8, Life Biosciences released its first interim data, covering three glaucoma patients at the lowest dose level. The company said the dose was tolerated through Day 56 with no serious side effects, and an independent safety board cleared the next, higher dose. It also reported that visual field improved in 2 of the 3 patients.
Treat that last number with great caution. Three people is a tiny sample, everyone knew they were getting the treatment, and the results come from a company release that has not been peer reviewed. Life Biosciences itself says the trial is built to test safety, and three patients cannot show that the therapy works.
By June 9, 2026, doctors in a clinical trial had slid a needle into a patient’s eye and injected a virus carrying a genetic switch designed to do something science has never safely done in a living person: turn back the biological clock inside human cells.
The therapy is called ER-100, and the company behind it, Boston-based Life Biosciences, was co-founded by the Harvard geneticist David Sinclair. It works by delivering three of the four so-called Yamanaka factors, the same genes that can revert an adult cell to a stem-cell-like state, but in a controlled dose meant to rejuvenate a cell without erasing what it is. A course of an antibiotic called doxycycline, taken by mouth, switches the genes on for eight weeks, then off. The trial plans to enroll 18 patients with glaucoma or a sudden optic-nerve stroke called NAION, conditions in which vision, once lost, does not come back.
- Partial reprogramming, which resets the chemical tags that tell genes when to switch on, is the most heavily funded idea in longevity science, and in 2026 it crossed from the lab bench into the first carefully controlled human trials.
- Life Biosciences dosed its first patient in June and released interim data on three patients in October. NewLimit raised $435 million in June. Retro Biosciences and Altos Labs are working nearby, with large budgets behind them.
- The cellular science is real. Whole-body age reversal that is safe and useful in healthy people is not proven. The human data is still measured in weeks and a handful of patients.
- The interventions with the strongest evidence for staying healthy longer are still the unglamorous ones, and they are the subject of the rest of this series.
An Eye Trial for a Longevity Idea
The eye is a sensible place to test a risky idea. It is walled off from the rest of the body and easy to reach and watch. A change in the retina can be measured directly. Life Biosciences received clearance from the U.S. Food and Drug Administration in January to run the trial, which it describes as the first epigenetic reprogramming therapy cleared to enter human testing for an age-related condition.
For a century, aging looked like one-way wear. Reprogramming is the first serious bet that some of that wear can be undone. If even a fraction of that bet pays off, it reframes medicine from treating age-related disease one at a time to slowing the process that produces them. That is the promise. The small trial now under way is where it meets reality.
NewLimit, Retro and Altos
On June 2, the startup NewLimit, co-founded by Coinbase chief executive Brian Armstrong, closed a $435 million round led by Founders Fund. NewLimit says its lead reprogramming factors restored youthful function to aged human liver cells. It has no human trial yet and plans to begin one in 2027, in liver disease.
Two better-known names work in the same field. Retro Biosciences has a cell-cleanup drug (an autophagy drug), RTR242, in a first-in-human study in healthy volunteers in Adelaide, Australia, according to Longevity.Technology; that drug is a small molecule and does not use reprogramming, and we found no Retro reprogramming trial in people. Altos Labs, which launched in 2022, is still preclinical as far as we could find. MIT Technology Review listed no other human partial-reprogramming trial in January 2026, and we found none since.
What the Lab Results Show
Lab results explain why serious scientists take this seriously. In May, researchers at the University of California, San Diego reported that the weight-loss drug semaglutide was associated with roughly nine percent slower biological aging, measured by a blood test of biological age called DunedinPACE, in a study of 108 adults with HIV-related metabolic changes. It is a narrow population and a secondary finding, short of proof that the drug slows aging, but it is the kind of signal that keeps the field busy.
Other advances are older than the headlines suggest. A striking method for selectively clearing damaged mitochondrial DNA, often cited as new, actually comes from a 2016 UCLA and Caltech study in fruit flies, where scientists removed about 95 percent of the damaged copies. Work showing that restoring the antioxidant glutathione revives tired muscle stem cells dates to 2023. These are real findings, laid years ago, and calling decade-old cell biology new news is how longevity coverage loses the plot.
From Cell to Person
One dosed patient and one big funding round prove little. The gap between a promising effect in a dish and a therapy that safely extends healthy human life is still wide, and it is measured in years of safety data. Reprogramming carries a specific fear: push the factors too hard and a rejuvenated cell can forget its job and turn cancerous. The trials are small and local precisely because the stakes are large.
So the reasonable posture is neither dismissal nor hype. Something genuine changed in 2026. The idea that biological age is partly reversible left the realm of pure theory and entered the clinic under real oversight.
Habits With Strong Evidence
For nearly everyone reading this, the highest-confidence steps for aging well are proven ones: progressive strength training, cardiovascular fitness, protected hearing, good sleep, enough protein, and a life with purpose and people in it. The evidence behind them is larger, longer, and more consistent than anything reprogramming has produced, and it is available today without a trial. That evidence, and how to weigh it against the science now entering the clinic, is what the remaining stories in this guide take up.
This article is health information, not medical advice. HeadLines Decoded reports on the science of aging. Talk to a qualified clinician before acting on anything described here.
Correction, September 24, 2026: An earlier version of this article described Coinbase chief executive Brian Armstrong only as a backer of NewLimit. He is one of its three co-founders, according to STAT. The article and its source list also linked the semaglutide finding to the wrong Nature Communications paper. Both links now go to the Corley et al. paper, published online May 19, 2026.
- Life Biosciences, “First Patient Dosed in Phase 1 Trial of ER-100,” June 9, 2026. Company release. Trial NCT07290244.
- STAT, “Longevity startup NewLimit announces $435 million financing,” June 2, 2026. Link.
- Longevity.Technology, “Retro Bio commences first-in-human trial,” RTR242. Link.
- Pulse 2.0, “NewLimit raises $435 million Series C.” Link.
- Life Biosciences, first-in-human interim data from the ER-100 phase 1 trial, October 8, 2026. Company release.
- Corley et al., semaglutide and pace of aging, Nature Communications, May 2026. Link.
- Kandul et al., selective clearance of mutant mitochondrial DNA, Nature Communications (UCLA/Caltech), 2016. UCLA summary.
- MIT Technology Review, “The first human test of a rejuvenation method will begin shortly,” January 27, 2026. Link.
Editor written. AI used for spelling and grammar only.
